180 related articles for article (PubMed ID: 21917606)
1. Potential role of HE4 in multimodal screening for epithelial ovarian cancer.
Urban N; Thorpe JD; Bergan LA; Forrest RM; Kampani AV; Scholler N; O'Briant KC; Anderson GL; Cramer DW; Berg CD; McIntosh MW; Hartge P; Drescher CW
J Natl Cancer Inst; 2011 Nov; 103(21):1630-4. PubMed ID: 21917606
[TBL] [Abstract][Full Text] [Related]
2. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
[TBL] [Abstract][Full Text] [Related]
3. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
4. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N
J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715
[TBL] [Abstract][Full Text] [Related]
5. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
6. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
[TBL] [Abstract][Full Text] [Related]
7. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.
Chang X; Ye X; Dong L; Cheng H; Cheng Y; Zhu L; Liao Q; Zhao Y; Tian L; Fu T; Chen J; Cui H
Int J Gynecol Cancer; 2011 Jul; 21(5):852-8. PubMed ID: 21633297
[TBL] [Abstract][Full Text] [Related]
8. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.
Lowe KA; Shah C; Wallace E; Anderson G; Paley P; McIntosh M; Andersen MR; Scholler N; Bergan L; Thorpe J; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2480-7. PubMed ID: 18768519
[TBL] [Abstract][Full Text] [Related]
9. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.
Andersen MR; Goff BA; Lowe KA; Scholler N; Bergan L; Drescher CW; Paley P; Urban N
Gynecol Oncol; 2010 Mar; 116(3):378-83. PubMed ID: 19945742
[TBL] [Abstract][Full Text] [Related]
10. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
11. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.
Van Gorp T; Cadron I; Despierre E; Daemen A; Leunen K; Amant F; Timmerman D; De Moor B; Vergote I
Br J Cancer; 2011 Mar; 104(5):863-70. PubMed ID: 21304524
[TBL] [Abstract][Full Text] [Related]
12. Bead-based ELISA for validation of ovarian cancer early detection markers.
Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
[TBL] [Abstract][Full Text] [Related]
13. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
Moore RG; McMeekin DS; Brown AK; DiSilvestro P; Miller MC; Allard WJ; Gajewski W; Kurman R; Bast RC; Skates SJ
Gynecol Oncol; 2009 Jan; 112(1):40-6. PubMed ID: 18851871
[TBL] [Abstract][Full Text] [Related]
14. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
[TBL] [Abstract][Full Text] [Related]
15. The role of transvaginal ultrasound in screening for ovarian cancer.
Campbell S; Gentry-Maharaj A
Climacteric; 2018 Jun; 21(3):221-226. PubMed ID: 29490504
[TBL] [Abstract][Full Text] [Related]
16. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
[TBL] [Abstract][Full Text] [Related]
17. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.
Gentry-Maharaj A; Burnell M; Dilley J; Ryan A; Karpinskyj C; Gunu R; Mallett S; Deeks J; Campbell S; Jacobs I; Sundar S; Menon U
Am J Obstet Gynecol; 2020 Jan; 222(1):56.e1-56.e17. PubMed ID: 31351062
[TBL] [Abstract][Full Text] [Related]
18. HE4: a new potential early biomarker for the recurrence of ovarian cancer.
Anastasi E; Marchei GG; Viggiani V; Gennarini G; Frati L; Reale MG
Tumour Biol; 2010 Apr; 31(2):113-9. PubMed ID: 20358424
[TBL] [Abstract][Full Text] [Related]
19. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]